ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

10% owner Icahn School of Medicine sells 147,141 shares (5.1% of holdings) for $10.4M at $70.64 avg

Icahn School of Medicine at Mount Sinai, a 10% shareholder in GeneDx Holdings, executed 2 separate open-market sales totaling 147,141 shares for $10,393,722.68 between November 15–18, 2024, reducing holdings from 2.87M to 2.72M shares. The company is unprofitable (net income of $-8,312,000 in the latest quarter, full-year net income negative) and revenue declined 13.7% year-over-year, which provides macroeconomic context for the transaction. The transactions occurred at prices ($69.78 and $70.78) near the current price of $71.04, reflecting no obvious anticipation of near-term price moves; prior same-ticker transaction timing outcome has not yet been measurable. This represents a moderate reduction in an already substantial position, with no evident cross-ticker sell pattern to frame whether this reflects insider outlook on the company specifically or broader portfolio management.

10% owner Mount Sinai sells 865,800 shares (23.2% reduction) of GeneDx at $75.00; stock up 50.9% in 30 days from unprofitable biotech

Icahn School of Medicine at Mount Sinai, a 10% institutional owner of GeneDx Holdings, executed a substantial sale of 865,800 shares on 2024-10-31 at $75.00, reducing holdings from 3,732,633 shares to 2,866,833 shares. The sale occurred amid a sharp 30-day rally of +50.9% and a 90-day surge of +160.8%, placing the stock at $75.00—close to its 52-week high of $84.02. This is particularly notable given GeneDx's financial profile: the company reported negative net income of $-8,312,000 in its latest quarter, operates with -13.7% annual revenue decline, and carries a market cap of $2,064,750,198.52. The divestiture of a meaningful portion of a major institutional stake warrants investor attention to whether the entity's funding or strategic priorities toward the company have shifted, especially given the recent price appreciation and unfavorable financial trajectory.